Drug intelligence / Profile preview

CM338

Development stage: Phase 2
Lead developer: Keymed Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

CM338 is a humanized monoclonal antibody developed by Keymed Biosciences. It acts as an antagonist of mannan-binding lectin-associated serine protease-2 (MASP2), thereby inhibiting the lectin pathway of complement activation. The drug is being investigated primarily for the treatment of immunoglobulin A (IgA) nephropathy and other kidney diseases, with its highest development phase being Phase 2 clinical trials in China. CM338 is administered via subcutaneous or intravenous injection.

Other names: cm338cm-338cm 338

Targets

MASP2 (Mannan-binding lectin-associated serine protease 2)

Beyond the preview

Go deeper on CM338.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM338.

Explore the full profile